Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies

Author: Benzinga Newsdesk | July 01, 2024 06:09am
  • Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025
  • Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market
  • It adds to Grifols' strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics
  • Yimmugo will be followed by other proteins in the pipeline, including fibrinogen and trimodulin, both in late-stage development

Posted In: GRFS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)
CORE Finalist